Literature DB >> 28224288

Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28224288     DOI： 10.1007/s00417-017-3617-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Re: Yeh et al.: Ophthalmic Technology Assessment: therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology (Ophthalmology 2015;122:769-78).

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Ophthalmology       Date:  2015-11       Impact factor: 12.079

2.  Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Authors:  Kai Januschowski; Nicolas Feltgen; Amelie Pielen; Bernhard Spitzer; Matus Rehak; Georg Spital; Spyridon Dimopoulos; Carsten H Meyer; Gesine B Szurman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-08       Impact factor: 3.117

Review 3.  TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.

Authors:  K Bailey Freund; Jean-François Korobelnik; Robert Devenyi; Carsten Framme; John Galic; Edward Herbert; Hans Hoerauf; Paolo Lanzetta; Stephan Michels; Paul Mitchell; Jordi Monés; Carl Regillo; Ramin Tadayoni; James Talks; Sebastian Wolf
Journal:  Retina       Date:  2015-08       Impact factor: 4.256

4.  Correspondence.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Retina       Date:  2016-11       Impact factor: 4.256

5.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

6.  Comment on: 'Central retinal vein occlusion: modifying current treatment protocols'.

Authors:  D Călugăru; M Călugăru
Journal:  Eye (Lond)       Date:  2016-04-22       Impact factor: 3.775

7.  Comment on: 'Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab'.

Authors:  D Călugăru; M Călugăru
Journal:  Eye (Lond)       Date:  2016-02-12       Impact factor: 3.775

8.  Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.

Authors:  David L Epstein; Peep V Algvere; Gunvor von Wendt; Stefan Seregard; Anders Kvanta
Journal:  Ophthalmology       Date:  2012-08-17       Impact factor: 12.079

9.  Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).

Authors:  Sandeep Grover; Ravi K Murthy; Vikram S Brar; Kakarla V Chalam
Journal:  Am J Ophthalmol       Date:  2009-05-09       Impact factor: 5.258

10.  Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography.

Authors:  Annie Chan; Jay S Duker; Tony H Ko; James G Fujimoto; Joel S Schuman
Journal:  Arch Ophthalmol       Date:  2006-02
  10 in total
  1 in total

1.  Ocular hypertension in patients with central/hemicentral retinal vein occlusions: cumulative prevalence and management.

Authors:  Dan Călugăru; Mihai Călugăru; Ştefan Ţălu
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.